MX2009005293A - Novedosos anticuerpos antiproliferacion. - Google Patents

Novedosos anticuerpos antiproliferacion.

Info

Publication number
MX2009005293A
MX2009005293A MX2009005293A MX2009005293A MX2009005293A MX 2009005293 A MX2009005293 A MX 2009005293A MX 2009005293 A MX2009005293 A MX 2009005293A MX 2009005293 A MX2009005293 A MX 2009005293A MX 2009005293 A MX2009005293 A MX 2009005293A
Authority
MX
Mexico
Prior art keywords
antibodies
novel
relates
present
antiproliferation antibodies
Prior art date
Application number
MX2009005293A
Other languages
English (en)
Inventor
Liliane Goetsch
Nathalie Corvaia
Jean-Francois Haeuw
Cedric Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2009005293A publication Critical patent/MX2009005293A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención está relacionada con anticuerpos aislados novedosos, o los compuestos derivados o fragmentos funcionales de los mismos, capaces de inhibir la proliferación de células tumorales in vitro y/o in vivo, dichos anticuerpos han sido obtenidos por tamizado funcional. Más particularmente la presente invención se relaciona con el anticuerpo 6F4, específico para la proteína JAM-A, como así también con su uso para el tratamiento del cáncer. También están cubiertas las composiciones farmacéuticas compuestas por tales anticuerpos.
MX2009005293A 2006-11-24 2007-11-23 Novedosos anticuerpos antiproliferacion. MX2009005293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation
PCT/EP2007/062760 WO2008062063A1 (en) 2006-11-24 2007-11-23 Novel antiproliferation antibodies

Publications (1)

Publication Number Publication Date
MX2009005293A true MX2009005293A (es) 2009-08-07

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005293A MX2009005293A (es) 2006-11-24 2007-11-23 Novedosos anticuerpos antiproliferacion.

Country Status (28)

Country Link
US (2) US8071730B2 (es)
EP (1) EP2074148A1 (es)
JP (1) JP2010509931A (es)
KR (1) KR20090088878A (es)
CN (1) CN101535344B (es)
AU (1) AU2007324509B2 (es)
BR (1) BRPI0719323A2 (es)
CA (1) CA2670039A1 (es)
CL (1) CL2007003357A1 (es)
CR (1) CR10788A (es)
CU (1) CU23792A3 (es)
EC (1) ECSP099341A (es)
FR (1) FR2909092B1 (es)
GE (1) GEP20125629B (es)
GT (1) GT200900126A (es)
HK (1) HK1132752A1 (es)
IL (1) IL198744A0 (es)
MA (1) MA30891B1 (es)
MX (1) MX2009005293A (es)
NI (1) NI200900079A (es)
NO (1) NO20092360L (es)
NZ (1) NZ576174A (es)
RU (1) RU2451689C2 (es)
SA (1) SA07280637B1 (es)
TN (1) TN2009000194A1 (es)
TW (1) TW200829602A (es)
UA (1) UA99602C2 (es)
WO (1) WO2008062063A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2011053759A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
SG189929A1 (en) * 2010-10-29 2013-06-28 Immunogen Inc Novel egfr-binding molecules and immunoconjugates thereof
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
AU2013306390B2 (en) 2012-08-24 2018-07-05 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
KR20190022752A (ko) 2016-06-27 2019-03-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
BR112019002127A2 (pt) * 2016-08-03 2019-09-17 Nextcure Inc proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
US6677436B1 (en) * 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
ATE500328T1 (de) * 1999-03-11 2011-03-15 Merck Serono Sa Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
WO2005060457A2 (en) * 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
EP1888639A1 (en) * 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
CA2650380A1 (en) * 2006-04-28 2007-11-08 Oregon Health & Science University Monoclonal antibodies and their use

Also Published As

Publication number Publication date
RU2451689C2 (ru) 2012-05-27
JP2010509931A (ja) 2010-04-02
MA30891B1 (fr) 2009-11-02
WO2008062063A1 (en) 2008-05-29
FR2909092B1 (fr) 2012-10-19
US20120156191A1 (en) 2012-06-21
EP2074148A1 (en) 2009-07-01
CL2007003357A1 (es) 2008-04-04
NI200900079A (es) 2010-11-10
RU2009123409A (ru) 2010-12-27
CR10788A (es) 2009-06-23
ECSP099341A (es) 2009-06-30
AU2007324509A1 (en) 2008-05-29
AU2007324509B2 (en) 2013-01-17
UA99602C2 (ru) 2012-09-10
US8071730B2 (en) 2011-12-06
GT200900126A (es) 2011-09-02
US20100092455A1 (en) 2010-04-15
BRPI0719323A2 (pt) 2014-02-04
TN2009000194A1 (en) 2010-10-18
NO20092360L (no) 2009-08-11
IL198744A0 (en) 2010-02-17
HK1132752A1 (en) 2010-03-05
CU23792A3 (es) 2012-03-15
KR20090088878A (ko) 2009-08-20
CN101535344A (zh) 2009-09-16
FR2909092A1 (fr) 2008-05-30
GEP20125629B (en) 2012-09-10
CN101535344B (zh) 2013-10-16
NZ576174A (en) 2012-03-30
SA07280637B1 (ar) 2012-04-11
CA2670039A1 (en) 2008-05-29
TW200829602A (en) 2008-07-16

Similar Documents

Publication Publication Date Title
TN2009000194A1 (en) Novel antiproliferation antibodies
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
TW200740844A (en) Novel MAdCAM antibodies
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
BRPI0923786C1 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
SG170080A1 (en) Human monoclonal antibodies to o8e
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
DE60028970D1 (de) An her2 bindende peptidverbindungen
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EP3539988A3 (en) Monoclonal antibodies against her2
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody

Legal Events

Date Code Title Description
FG Grant or registration